| Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer SM Tolaney, WT Barry, CT Dang, DA Yardley, B Moy, PK Marcom, ... New England Journal of Medicine 372 (2), 134-141, 2015 | 869 | 2015 |
| Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis LM Spring, G Fell, A Arfe, C Sharma, R Greenup, KL Reynolds, BL Smith, ... Clinical cancer research 26 (12), 2838-2848, 2020 | 704 | 2020 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 701 | 2017 |
| Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 … A Chan, S Delaloge, FA Holmes, B Moy, H Iwata, VJ Harvey, NJ Robert, ... The Lancet Oncology 17 (3), 367-377, 2016 | 684 | 2016 |
| Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: phase III NALA trial C Saura, M Oliveira, YH Feng, MS Dai, SW Chen, SA Hurvitz, SB Kim, ... Journal of Clinical Oncology 38 (27), 3138-3149, 2020 | 539 | 2020 |
| Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future LM Spring, SA Wander, F Andre, B Moy, NC Turner, A Bardia The Lancet 395 (10226), 817-827, 2020 | 406 | 2020 |
| Neoadjuvant endocrine therapy for estrogen receptor–positive breast cancer: a systematic review and meta-analysis LM Spring, A Gupta, KL Reynolds, MA Gadd, LW Ellisen, SJ Isakoff, ... JAMA oncology 2 (11), 1477-1486, 2016 | 393 | 2016 |
| TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2–positive breast cancer and brain metastases RA Freedman, RS Gelman, CK Anders, ME Melisko, HA Parsons, ... Journal of Clinical Oncology 37 (13), 1081-1089, 2019 | 348 | 2019 |
| Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2–negative (or unknown) advanced breast cancer: American Society of Clinical Oncology … AH Partridge, RB Rumble, LA Carey, SE Come, NE Davidson, A Di Leo, ... Journal of clinical oncology 32 (29), 3307-3329, 2014 | 308 | 2014 |
| Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2–positive breast cancer SM Tolaney, H Guo, S Pernas, WT Barry, DA Dillon, L Ritterhouse, ... Journal of Clinical Oncology 37 (22), 1868-1875, 2019 | 306 | 2019 |
| Institutional academic− industry relationships EG Campbell, JS Weissman, S Ehringhaus, SR Rao, B Moy, ... JAMA 298 (15), 1779-1786, 2007 | 277 | 2007 |
| Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study I Vaz-Luis, RA Ottesen, ME Hughes, R Mamet, HJ Burstein, SB Edge, ... Journal of Clinical Oncology 32 (20), 2142-2150, 2014 | 271 | 2014 |
| Long‐term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer AB Kornblith, M Powell, MM Regan, S Bennett, C Krasner, B Moy, ... Psycho‐Oncology: Journal of the Psychological, Social and Behavioral …, 2007 | 271 | 2007 |
| Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline S Dhesy-Thind, GG Fletcher, PS Blanchette, MJ Clemons, MS Dillmon, ... Journal of Clinical Oncology 35 (18), 2062-2081, 2017 | 264 | 2017 |
| Comparison of the genomic landscape between primary breast cancer in African American versus white women and the association of racial differences with tumor recurrence T Keenan, B Moy, EA Mroz, K Ross, A Niemierko, JW Rocco, S Isakoff, ... Journal of Clinical Oncology 33 (31), 3621-3627, 2015 | 260 | 2015 |
| Lapatinib: current status and future directions in breast cancer B Moy, PE Goss The oncologist 11 (10), 1047-1057, 2006 | 244 | 2006 |
| Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial A Chan, B Moy, J Mansi, B Ejlertsen, FA Holmes, S Chia, H Iwata, ... Clinical breast cancer 21 (1), 80-91. e7, 2021 | 237 | 2021 |
| Mammographic breast density and race MG del Carmen, EF Halpern, DB Kopans, B Moy, RH Moore, PE Goss, ... American Journal of Roentgenology 188 (4), 1147-1150, 2007 | 229 | 2007 |
| Lapatinib. B Moy, P Kirkpatrick, S Kar, P Goss Nature reviews drug discovery 6 (6), 2007 | 211 | 2007 |
| Clinical management of potential toxicities and drug interactions related to cyclin‐dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations LM Spring, ML Zangardi, B Moy, A Bardia The oncologist 22 (9), 1039-1048, 2017 | 185 | 2017 |
